Ahead of the launch, Shri Prataprao Jadhav, Union Minister of State (IC) for Ayush and Minister of State for Health & Family Welfare, Government of India, mentioned, “SIDDHI 2.0 represents our continuous efforts and commitment to boost the Traditional Medicine sector and transform Ayush into a system that stands firmly on scientific foundations. CCRAS has created a strong national platform for innovation, and its engagement with industry is crucial for transforming research outcomes into high-quality Ayurvedic products that meet global expectations.”
Also Read:Safdarjung Hospital partners with Central Ayurveda Research Institute to boost menopause care
Vaidya Rajesh Kotecha, Secretary, Ministry of Ayush, emphasised, “Ayurveda’s future lies in its ability to convert validated research into accessible and reliable solutions. SIDDHI 2.0 is a timely initiative that brings together CCRAS’ scientific strength and the manufacturing capabilities of India’s Ayush industry, enabling faster product development and smoother regulatory pathways”, the PIB stated.
Building on the momentum generated by CCRAS’ PRAGATI-2024 (Pharma Research in Ayurgan and Techno Innovation) initiative last year, SIDDHI 2.0 marks a decisive shift towards research-led product development, indigenous technologies, and faster translational pipelines—priorities at the heart of India’s current Ayush innovation strategy.
Prof. Rabinarayan Acharya, Director General, CCRAS, highlighted the key features of the program and informed, “This two-day programme has been structured as a focused engagement that aligns CCRAS’ scientific work with industrial application. It will showcase CCRAS’ research outcomes, match them with industry requirements, and create actionable pathways for product development, validation, and scale-up. By bringing researchers, manufacturers, regulators, and clinicians together, the programme will accelerate Ayurveda’s transition toward a more evidence-driven, innovation-ready future.”
The initiative is being driven by the scientific leadership of CCRAS, which has articulated a strong national vision for evidence-based Ayurveda. CCRAS is poised to outline India’s rapidly evolving Ayurvedic research ecosystem, playing a central role in drug development, standardisation, validation, regulatory advancement, and commercialisation.
The event, SIDDHI 2.0, will be graced by Shri K. Dinesh Kumar, IAS, Director (Ayush), Government of Andhra Pradesh, and Dr. N. Srikanth, Deputy Director General, CCRAS. The meet will also bring together over 25 leading Ayurvedic pharmaceutical companies from Southern India—including Himalaya, Oushadhi, IMPCOPS, Laila Nutra Pvt. Ltd., and Imis Pharmaceuticals—along with researchers, clinicians, academic experts, State Ayush representatives, and postgraduate scholars from NRS Ayurvedic College, Vijayawada.
Positioned as a national translational accelerator, SIDDHI 2.0 aims to expand industry adoption of CCRAS technologies, strengthen institutional networks, enhance quality and regulatory systems, and support the development of globally competitive Ayurvedic pharmaceuticals. By advancing scientific innovation and industrial collaboration in tandem, SIDDHI 2.0 sets the stage for a new era of evidence-based Ayurveda aligned with India’s vision for holistic, modern, and scalable traditional medicine.
Also Read:AYUSH Ministry, WHO host Ambassadors' Reception ahead of 2nd Global Summit on Traditional Medicine
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.